China: OST completes Series C financing, which is jointly led by Temasek and Taikang Asset Management
n June 25th, OST(Orient Speech Therapy Center), a leading domestic child speech rehabilitation and autism intervention institution, announced completion of C2 round financing of 60 million US dollars, which was jointly led by Temasek and Taikang Asset Management. Taihe Capital continues to act as its exclusive financial advisor. This round of financing has also become the largest single round of financing in the field of children's speech rehabilitation and autism intervention. In the company's history, it has received investment from Eight Roads and its sister fund F-Prime Capital, Northern Light Venture Capital, and Long Hill Capital.
Following the C1 round of financing in February 2021, OST has completed a total of US$83 million in Series C financing within 4 months. This round of financing will be used to further expand the network layout of directly operated centers in cities across the country, accelerate clinical practice and curriculum development, and cooperate with authoritative universities at home and abroad to build a speech rehabilitation therapist training and growth system. In the future, OST will continue to extend the scope of courses to cover different levels of needs, build a scientific and technological rehabilitation service ecology through effective resource integration, realize the integrated management of "online + offline", in order to provide children in needs with one-stop solution plans for rehabilitation and development. OST will also firmly promote the localization of international standards for children's speech and autism intervention.
Founded in 2007, OST is committed to children's speech rehabilitation and autism intervention, helping children overcome developmental and learning disabilities, and providing professional services in children's speech development and early screening, clinical training and autism intervention. Meanwhile, OST continues to increase strategic investment in localization of international advanced technology, clinical technology improvement, curriculum product research and development, and professional talent training.
source: Nanfang Metropolis Daily
translation: InsurView
https://www.reddit.com/r/StockMarket/comments/o9gb31/china_ost_completes_series_c_financing_which_is/
